Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
Does treating CLL reduce the risk of non-melanoma skin cancers?
Related Questions
How long do you continue ursodiol for VOD prophylaxis after gemtuzumab ozogamicin for good-risk AML
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?
What are the treatment options for relapsed T-ALL in a patient who was nonadherent with AALL and hyper-CVAD regimens?
How would you treat a patient with newly diagnosed low-risk acute promyelocytic leukemia who has a baseline wide QTc interval, such that arsenic trioxide cannot be used?
Do you add venetoclax +/- anti CD-20 mAb to a BTKi in patients with CLL who no longer wish to remain on a BTKi many months after starting the BTKi?
